Przeglad gastroenterologiczny · 2026
Oncostatin M as a key predictive factor for anti-TNF-α response in inflammatory bowel disease.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kaniewska Magdalena, Lewandowski Konrad, Zagozda Małgorzata, Wilk Juliusz, Cicha Małgorzata, Rydzewska Grażyna M
Аннотация
INTRODUCTION: Reliable biomarkers are needed to predict response to anti-TNF-α therapy in patients with inflammatory bowel disease.
AIM: The primary aim of this study was to evaluate the usefulness of serum oncostatin M (OSM) as a marker of response to anti-TNF-α therapy in patients with inflammatory bowel disease (IBD). A secondary endpoint was the identification of additional factors that may influence the response to anti-TNF-α treatment.
MATERIAL AND METHODS: The study included 135 patients treated with infliximab or adalimumab. Serum OSM and faecal calprotectin levels were measured at baseline and after 14 weeks of therapy.
RESULTS: Baseline OSM levels were significantly lower in responders than in non-responders (MD = -348.07; 95% CI: -400.72 to -242.96; p < 0.001) and demonstrated high accuracy in predicting treatment outcomes (AUC = 0.908; 95% CI: 0.848-0.960; p < 0.001). Patients with baseline OSM concentrations below 216.82 pg/ml were more likely to respond to therapy, with a sensitivity of 92% and a specificity of 77%. Baseline faecal calprotectin levels showed low-to-moderate predictive value for treatment response (AUC = 0.690; 95% CI: 0.589-0.780; p = 0.005). A significant difference in treatment response was observed with respect to prior exposure to biologic therapy (23.9% vs. 69.8%; p < 0.001), with a moderate association strength as measured by Cramér's V (V = 0.44; 95% CI: 0.28-0.59).
CONCLUSIONS: Several factors - including age, disease location, concomitant IBD-associated spondyloarthropathy, calprotectin levels - may influence the response to anti-TNF-α therapy. However, only low serum OSM concentration was consistently associated with a better treatment response and may represent a promising biomarker and potential therapeutic target in IBD.
AIM: The primary aim of this study was to evaluate the usefulness of serum oncostatin M (OSM) as a marker of response to anti-TNF-α therapy in patients with inflammatory bowel disease (IBD). A secondary endpoint was the identification of additional factors that may influence the response to anti-TNF-α treatment.
MATERIAL AND METHODS: The study included 135 patients treated with infliximab or adalimumab. Serum OSM and faecal calprotectin levels were measured at baseline and after 14 weeks of therapy.
RESULTS: Baseline OSM levels were significantly lower in responders than in non-responders (MD = -348.07; 95% CI: -400.72 to -242.96; p < 0.001) and demonstrated high accuracy in predicting treatment outcomes (AUC = 0.908; 95% CI: 0.848-0.960; p < 0.001). Patients with baseline OSM concentrations below 216.82 pg/ml were more likely to respond to therapy, with a sensitivity of 92% and a specificity of 77%. Baseline faecal calprotectin levels showed low-to-moderate predictive value for treatment response (AUC = 0.690; 95% CI: 0.589-0.780; p = 0.005). A significant difference in treatment response was observed with respect to prior exposure to biologic therapy (23.9% vs. 69.8%; p < 0.001), with a moderate association strength as measured by Cramér's V (V = 0.44; 95% CI: 0.28-0.59).
CONCLUSIONS: Several factors - including age, disease location, concomitant IBD-associated spondyloarthropathy, calprotectin levels - may influence the response to anti-TNF-α therapy. However, only low serum OSM concentration was consistently associated with a better treatment response and may represent a promising biomarker and potential therapeutic target in IBD.